B
BioSpace
Why investors are taking another look at kidney disease
0:00-18:26
In this episode of Denatured, you’ll hear from Bruce Culleton, CEO at ProKidney and Demetri Maxim, CEO at Nephrogen. We discuss why kidney disease has long been a hard target for cell and gene therapies, and what new delivery strategies, therapeutic approaches and regulatory clarity mean for commercially viable products.HostJennifer C. Smith-Parker, Director of Insights, BioSpaceGuestsBruce Culleton, CEO, ProKidneyDemetri Maxim, CEO, NephrogenDisclaimer: The views expressed in this discussion by guests are their own and do not re...
Publisher
BioSpace
Published
October 22, 2026
Duration
18 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#investors #taking #kidneydisease #lifesciences
